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Summary
The role of transforming growth factor-b (TGF-b) in
inhibiting T cell functions has been studied with domi-
nant-negative TGF-b receptor transgenic models;
however, the full impact of TGF-b signaling on T cells
and the mechanisms by which TGF-b signals remain
poorly understood. Here we show that mice with T
cell-specific deletion of TGF-b receptor II developed le-
thal inflammation associated with T cell activation and
differentiation. In addition, TGF-b signaling positively
regulated T cell development and homeostasis. Devel-
opment of CD8+ T cells and NKT cells, maintenance of
peripheral Foxp3-expressing regulatory T cells, and
survival of CD4+ T cells all depended on TGF-b signal-
ing. Both T helper 1 (Th1) differentiation and survival
of activatedCD4+ T cells required T-bet, the TGF-b-reg-
ulated transcription factor, which controlled CD122
expression and IL-15 signaling in Th1 cells. This study
reveals pleiotropic functions of TGF-b signaling in
T cells that may ensure a diverse and self-tolerant
T cell repertoire in vivo.
Introduction
The stochastic nature of T cell receptor (TCR) rearrange-
ment results in a plethora of T cell clones that are sub-
jected to the processes of positive and negative selec-
tion in the thymus. T cell clones with low-affinity TCRs
to self antigens are positively selected, whereas T cells
with high-affinity TCR interactions are mostly eliminated
by negative selection to prevent the development of au-
toimmunity (Starr et al., 2003). A subset of self-reactive T
cells avoid being destroyed in the thymus and further dif-
ferentiate into mature T cells with regulatory activities;
these include CD4+CD25+ regulatory T (Treg) cells and
CD1d-dependent natural killer T (NKT) cells (Kronenberg
and Rudensky, 2005). The Treg cell lineage, specified by
the transcription factor Foxp3, essentially regulates pe-
ripheral T cell tolerance, as shown by the fact that mice
and humans that lack these cells develop severe autoim-
mune diseases (Maloy and Powrie, 2001; Sakaguchi,
2004; Shevach, 2000). On the other hand, activation of
NKT cells can prevent or exaggerate autoimmunity de-
pending on the disease model (Kronenberg, 2005).
Transforming growth factor-b (TGF-b) family consists
of potent regulatory molecules that play an essential role
in T cell tolerance (Gorelik and Flavell, 2002). There are
three TGF-b isoforms in mammals, TGF-b1, TGF-b2,
*Correspondence: richard.flavell@yale.eduand TGF-b3, which signal through two trans-membrane
serine-threonine kinase receptors, TGF-b receptor I and
II (TGF-bRI, TGF-bRII) (Massague, 1998). Among the
three TGF-b isoforms, TGF-b1 is predominantly ex-
pressed in the immune system (Govinden and Bhoola,
2003). Deficiency of TGF-b1 results in an early lethal au-
toimmune phenotype in mice (Kulkarni et al., 1993; Shull
et al., 1992), which is associated with circulating IgG an-
tibodies to nuclear antigens and a progressive infiltra-
tion of leukocytes into multiple organs (Dang et al.,
1995; Yaswen et al., 1996). T cells appear to be key me-
diators of the autoimmune disease in these mice, be-
cause depletion of CD4+ or CD8+ T cells alleviates the in-
flammatory phenotype (Kobayashi et al., 1999; Letterio
et al., 1996).
Because TGF-b1 can modulate the activity of multiple
cell types (Li et al., 2006), it was not clear from the early
studies whether T cells are direct targets of TGF-b1.
Several groups have used transgenic approaches to in-
hibit TGF-b signaling in T cells. Expression of a domi-
nant-negative TGF-bRII from the CD4 promoter (CD4-
DNRII) leads to the generation of autoantibodies and
the development of an inflammatory disease, but the
mice survive to adulthood (Gorelik and Flavell, 2000).
In another report, expression of DNRII from theCD2 pro-
moter results in a CD8+ T cell lymphoproliferative disor-
der with little inflammation (Lucas et al., 2000). This dif-
ference could be due to the expression pattern and/or
strength of the promoters used; alternatively, these
transgenic mice may have only a partial loss of function
of TGF-b signaling in T cells. Consistent with this, dele-
tion of TGF-bRII in bone marrow cells results in a more
severe inflammatory phenotype in mice (Leveen et al.,
2002). However, because T cells are not the only cell
type targeted in this model, it is possible that inhibition
of TGF-b signaling in cell types other than T cells con-
tributes to the stronger inflammatory phenotype. Thus,
the ultimate role of TGF-b signaling in T cells remains
to be established.
A recent study revealed that Tgfb12/2 mice fail to
maintain peripheral Treg cells (Marie et al., 2005). Inter-
estingly, the autoimmune phenotype developed in
Tgfb12/2 mice resembles that of Foxp32/2 mice, which
possess a specific defect of Treg cells (Fontenot et al.,
2003). Therefore, it is an open question whether the T
cell activation phenotype in Tgfb12/2 mice is due to
loss of Treg cells and/or is a consequence of lack of
Treg cell-independent control of T cell tolerance by
TGF-b1. It has been well documented that TGF-b po-
tently inhibits T cell proliferation and differentiation (Gor-
elik and Flavell, 2002). However, TGF-b induces the dif-
ferentiation of Treg cells in vitro (Chen et al., 2003;
Fantini et al., 2004; Wan and Flavell, 2005). Because
Treg cells potently inhibit T cell proliferation and differ-
entiation (Sakaguchi, 2004), it is not known whether
the suppressive activity of TGF-b on T cells represents
an autonomous pathway and/or is secondary to its in-
duction of Treg cells.
The exact molecular mechanism responsible for the
expansion and differentiation of T cells in Tgfb12/2
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not known. CD4+ T cells in CD4-DNRII mice differentiate
into both IFN-g-producing T helper 1 (Th1) cells and IL-
4-producing Th2 cells in vivo (Gorelik and Flavell, 2000).
In vitro, TGF-b inhibition of CD4+ effector T cell differen-
tiation has been attributed to its blockade of the expres-
sion of transcription factors T-bet in Th1 cells and
GATA-3 in Th2 cells (Neurath et al., 2002; Gorelik et al.,
2000, 2002; Heath et al., 2000). However, whether TGF-
b exerts its in vivo effects by also modulating the func-
tion of these transcription factors remains unknown.
To determine a definitive function of TGF-b signaling
in T cells in vivo, we generated mice with a T cell-specific
deletion of TGF-bRII. CD8+ T cell maturation and the de-
velopment of NKT cells were inhibited in the thymus. In
the periphery, Treg cells were reduced, and T cells were
activated and differentiated notably into T-bet-express-
ing Th1 cells. T-bet determined both the IFN-g expres-
sion and the survival of CD4+ T cells, which was associ-
ated with the expression of CD122. Deletion of TGF-bRII
in OT-II Rag12/2 T cells led to their partial activation and
massive apoptosis in the periphery. These findings re-
vealed both regulatory T cell-dependent and -indepen-
dent mechanisms of T cell development, tolerance,
and homeostasis specified by TGF-b signaling in T cells.
Results
Development of Lethal Autoimmunity in the Absence
of TGF-b Signaling in T Cells
Previous studies with transgenic expression of domi-
nant-negative TGF-bRII in T cells have shown varying
phenotypes (Gorelik and Flavell, 2000; Lucas et al.,
2000). We sought to determine a definitive function of
TGF-b signaling in T cells by crossing a strain of floxed
TGF-bRII mice (RII) with CD4-Cre transgenic mice
(4cre) (Chytil et al., 2002; Lee et al., 2001). The Cre trans-
gene in 4cre mice is expressed in CD4+CD8+ immature
thymocytes (Lee et al., 2001). Consistent with this,
CD4+CD8+ thymocytes in 4cre-RII/RII mice had no de-
tectable surface TGF-bRII compared to that of control
RII/RII mice (Figure 1A). Peripheral CD4+ and CD8+ T
cells were also devoid of surface TGF-bRII (Figure 1A).
Exogenous TGF-b induced Smad2 and Smad3 nuclear
translocation in RII/RII CD4+ T cells, which could not
be detected in 4cre-RII/RII CD4+ T cells (Figure 1B).
TGF-b-induced Smad2 phosphorylation was also not
detectable in 4cre-RII/RII CD4+ T cells, whereas there
was normal signaling in both RII/RII and heterozygous
4cre-RII/+ T cells (data not shown). These data demon-
strate efficient deletion of TGF-bRII and abrogation of
TGF-b signaling in 4cre-RII/RII T cells.
RII/RII and 4cre-RII/+ mice appeared healthy and had
no signs of autoimmunity (Figure 1C and data not
shown). In contrast, all 4cre-RII/RII mice developed
a progressive wasting disease and succumbed to death
before 5 weeks of age. Histological analysis revealed
heavy infiltration of leukocytes into multiple tissues
including stomach, lung, liver, pancreatic islets, and
thyroid gland of 4cre-RII/RII mice but not those of 4cre-
RII/+ mice (Figure 1C). Higher amounts of DNA autoanti-
body were also detected in the sera of 4cre-RII/RII mice
(Figure 1D), suggesting that impaired TGF-b signaling in
T cells results in the loss of B cell tolerance to self anti-gens. Similar leukocyte infiltration and development of
nuclear antigen antibody is observed in aged CD4-DNRII
transgenic mice (Gorelik and Flavell, 2000); however,
CD4-DNRII mice survive to adulthood, and the inflam-
matory phenotype in CD4-DNRII mice is much less se-
vere than that developed in 4cre-RII/RII mice. In fact,
TGF-b treatment of CD4-DNRII CD4+ T cells led to low
but detectable nuclear translocation of Smad2 and
Smad3 albeit reduced compared to that in control T cells
(data not shown). Therefore, the previously reported
dominant-negative TGF-bRII transgenic mice, which de-
velop varying degrees of inflammation, most likely pos-
sess incomplete loss of function of TGF-b signaling in T
cells. It is noteworthy that the wasting and inflammatory
phenotype of 4cre-RII/RII mice was comparable in se-
verity to that of Tgfb12/2mice (Kulkarni et al., 1993; Shull
et al., 1992), which highlights T cells as the key target of
TGF-b1-mediated immune tolerance.
Inhibited Thymic CD8+ T Cell Maturation
and Compromised Peripheral T Cell Tolerance
in 4cre-RII/RII Mice
To investigate the consequences of loss of TGF-b signal-
ing in T cells, we first evaluated thymic T cell develop-
ment in 4cre-RII/RII mice that were around 14 days
old. At this age, 4cre-RII/RII mice appeared healthy
and had comparable thymic cellularity to littermate con-
trols, compared to older mice that had involuted thymus
resulting from peripheral inflammation (data not shown).
The CD4 and CD8 profile of 4cre-RII/RII thymocytes was
not drastically different from that of control thymocytes,
although a substantial reduction of CD8+ T cells was ob-
served (Figure 2A). Mouse thymic CD8+ T cells are com-
prised of both the mature and the immature single-pos-
itive T cells (Paterson and Williams, 1987). To study the
mature T cell compartment, we first gated on the mature
TCR-bhi T cells (see Figure S1A in the Supplemental Data
available online). Among the TCR-bhi T cells, a 2-fold in-
crease of CD4+CD8+TCR-bhi T cells was observed in
4cre-RII/RII mice (Figure 2B and Figure S1A). The num-
ber of CD4+TCR-bhi T cells was comparable, but the
number of CD8+TCR-bhi T cells was reproducibly re-
duced by 50% in 4cre-RII/RII mice (Figure 2B and
Figure S1A). These observations reveal a function for
TGF-b signaling in the maturation of CD8+TCR-bhi
T cells.
TGF-b potently suppresses T cell proliferation in vitro
(Kehrl et al., 1986). To determine whether TGF-b affected
T cell expansion in vivo, CD4+ and CD8+ T cell numbers
were compared in the periphery. CD4+ and CD8+ T cell
numbers in the spleens and lymph nodes were signifi-
cantly higher in 4cre-RII/RII mice compared to littermate
controls (Figure 2C). To determine whether the T cell ex-
pansion phenotype was associated with increased T cell
proliferation, we pulse-labeled 4cre-RII/RII or the con-
trol RII/+ mice with BrdU for 16 hr. Foxp3-expressing
Treg cells were excluded in the analysis by gating on
CD4+Foxp32 and CD8+ T cells. During the 16 hr time
window, we observed 5- to 6-fold increase of BrdU-pos-
itive T cells in the spleens of 4cre-RII/RII mice (Fig-
ure 2D). An increase in BrdU-positive T cells was also
detected in the lymph nodes of 4cre-RII/RII mice (data
not shown). These data demonstrate that similar to
in vitro observations, in vivo blockade of TGF-b signaling
In Vivo Function of TGF-b Signaling in T Cells
457Figure 1. Abrogation of TGF-b Signaling in T Cells Led to Lethal Autoimmunity
(A) Surface staining of TGF-bRII (blue) in thymic (Thy) CD4+CD8+ and lymph node (LN) CD4+ and CD8+ T cells. The binding of an isotype control
antibody is shown in red. These are representative results of two independent experiments.
(B) RII/RII or 4cre-RII/RII CD4+ T cells were stimulated with anti-CD3 and anti-CD28 for 24 hr in the absence or presence of TGF-b. The amounts of
Smad2 and Smad3 and HDAC-1 in the nuclear extracts were determined by immunoblotting.
(C) Hematoxylin and eosin staining of stomach, lung, liver, pancreas, and thyroid gland sections from the tissues of 4cre-RII/RII and 4cre-RII/+
mice (2003) at 21 days old. These are representative results of five independent experiments.
(D) Titers of dsDNA antibody in the sera of 4cre-RII/RII (KO), or littermate RII/RII and 4cre-RII/+ (control) mice aged between 21 and 26 days
(n = 8). The p value between the two groups of dsDNA antibody titers is shown.in T cells results in a lymphoproliferative phenotype in
peripheral lymphoid organs.
Peripheral CD4+ and CD8+ T cells in 4cre-RII/RII mice
had an activated phenotype as measured by CD44 and
CD62L expression (CD44hiCD62Llo) (Figure 2E) and by
the high expression of adhesion molecules CD18 and
CD11a (Figure S1B). These T cells also expressed high
amounts of CD43 (Figure S1C), a marker associatedwith effector T cells (Onami et al., 2002). To determine
the cytokine production, as a measure of T cell differen-
tiation, we stimulated lymph node T cells ex vivo with
phorbol 12-myristate 13-acetate (PMA) and ionomycin
for 4 hr and performed intracellular cytokine staining.
In contrast to 4cre-RII/+ CD4+ T cells, which had only
a few cells capable of producing IFN-g or IL-4, the
majority of 4cre-RII/RII CD4+ T cells produced high
Immunity
458Figure 2. TGF-b Signaling in T Cells Was Required for the Maturation of Thymic CD8+ T Cells and the Inhibition of Peripheral T Cell Proliferation,
Activation, and Differentiation
(A) The thymic CD4 and CD8 profile of 4cre-RII/+ and 4cre-RII/RII mice at 16 days old (left and middle). The percentage of thymic CD8+ T cells in
4cre-RII/RII (KO) or littermate RII/RII and 4cre-RII/+ (control) mice (n = 8) aged between 14 and 16 days (right).
(B) Number of thymic TCR-bhi T cells expressing CD4 and CD8 (DP), CD4, or CD8 in 4cre-RII/RII (KO) or littermate RII/RII and 4cre-RII/+ (control)
mice (n = 4) aged between 14 and 16 days.
(C) Number of CD4+ or CD8+ T cells in the spleens (SP) and lymph nodes (LN) of 4cre-RII/RII (KO) or littermate RII/RII and 4cre-RII/+ (control) mice
(n = 7) at 19–26 days of age.
(D) BrdU staining of splenic CD4+Foxp32 and CD8+ T cells in RII/+ and 4cre-RII/RII mice at 16 days old. These are representative results of two
independent experiments.
(E) Expression of CD44 and CD62L of CD4+ and CD8+ T cells isolated from the lymph nodes of 4cre-RII/+ (top) and 4cre-RII/RII (bottom) mice at 16
days old. These are representative results of eight independent experiments.
(F) CD4+ and CD8+ T cells isolated from the lymph nodes of 4cre-RII/+ or 4cre-RII/RII mice were stimulated with PMA and ionomycin for 4 hr and
analyzed for the expression of IFN-g and IL-4 by intracellular cytokine staining. These are representative results of five independent experiments.
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(A) The percentage of CD4+Foxp3+ Treg cells among CD4+TCR-bhi T cells in 4cre-RII/RII (KO), or littermate RII/RII and 4cre-RII/+ (control) mice
(n = 4) is plotted. Thy, thymus; SP, spleen; LN, lymph node.
(B) BrdU staining of thymic, splenic, and lymph node CD4+Foxp3+ T cells in RII/+ and 4cre-RII/RII mice at 16 days old. These are representative
results of two independent experiments.
(C) Thymic and splenic TCR-bhiCD1d-aGalCer+ NKT cells in 4cre-RII/RII or RII/RII littermates at 16 days old (left and middle). The percentage of
thymic and splenic NKT cells in 4cre-RII/RII (KO) or littermate RII/RII and 4cre-RII/+ (control) mice (n = 5) aged between 14 and 16 days (right).amounts of IFN-g but not IL-4 (Figure 2F). Increased IFN-
g-positive cells were also observed in 4cre-RII/RII CD8+
T cells (Figure 2F). To investigate whether 4cre-RII/RII T
cells produced increased IFN-g in vivo, 4cre-RII/+ or4cre-RII/RII mice were injected with Brefeldin A. 6 hr
later, the expression of IFN-g was determined from T
cells isolated from the lymph nodes of these mice. A
higher percentage of 4cre-RII/RII CD4+ and CD8+ T cells
Immunity
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(A and B) Wild-type Treg cells were injected into neonatal mice.
(A) The percentage of donor and host CD4+Foxp3+ Treg cells among CD4+ T cells in the spleens (SP, top) or the lymph nodes (LN, bottom) of 4cre-
RII/RII (KO) or littermate RII/RII and 4cre-RII/+ (control) mice (n = 3) is plotted. The p values depict the difference of the donor Treg cells between
the KO and control groups. These are representative results of two independent experiments. The error bars have been calculated with Excel
STDEV, which gives the standard deviation.
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Therefore, ablation of TGF-b signaling in T cells led to
their activation and differentiation associated with the
development of a lethal autoimmune syndrome.
Inhibited Thymic NK T Cell Development and
Reduced Peripheral Treg Cells in 4cre-RII/RII Mice
Thymic T cell selection results in the generation of sub-
sets of T cells that play important roles in regulating im-
munity and tolerance (Kronenberg and Rudensky, 2005).
One type of such T cells is the Foxp3-expressing Treg
cells that essentially control peripheral T cell tolerance
(Sakaguchi, 2004). To investigate the role of TGF-b sig-
naling in Treg cells, we first studied Treg cell develop-
ment in 4cre-RII/RII mice. An increase in the percentage
and number of CD4+Foxp3+ T cells was observed
among CD4+TCR-bhi T cells from thymus of 14-day-old
4cre-RII/RII mice (Figure 3A and data not shown). Con-
sistent with this, a 2-fold higher percentage of 4cre-
RII/RII thymic Treg cells incorporated BrdU during a 16
hr pulse-labeling period (Figure 3B). These observations
reveal a previously unknown function for TGF-b in inhib-
iting the proliferation of thymic Treg cells.
Despite increased number of thymic Treg cells, the
number of peripheral Treg cells was not markedly differ-
ent between 14-day-old 4cre-RII/RII mice and the con-
trol mice (data not shown). However, when 4cre-RII/RII
mice were aged to about 21 days, a decrease in the per-
centage of Treg cells among CD4+ T cells was observed,
which was more pronounced in the spleens than in the
lymph nodes of these mice (Figure 3A). A previous study
showed that Treg cells expressing a dominant-negative
mutant of TGF-bRII failed to proliferate in a transfer
model of colitis (Huber et al., 2004). To study whether
decreased Treg cells in peripheral tissues was a conse-
quence of failed proliferation, 4cre-RII/RII and RII/+ mice
were pulse labeled with BrdU for 16 hr. Unexpectedly in-
creased rather than decreased BrdU-positive Treg cells
were detected in both the spleens and the lymph nodes
of the 4cre-RII/RII mice (Figure 3B). These observations
demonstrate that although TGF-b inhibits Treg cell pro-
liferation, it is required for the maintenance of peripheral
Treg cells. Because the cell number is a reflection of
both the rate of proliferation and death, TGF-b signaling
is likely essential for the survival of Treg cells in the
periphery.
In addition to Treg cells, NKT cells are another major
lineage of self-reactive T cells with an important function
in immunity and tolerance. NKT cells express receptors
that are also expressed on natural killer cells and TCRs
that recognize glycolipids presented by the CD1d mole-
cule (Bendelac et al., 1997). Most NKT cells expressVa14Ja18 TCRs and are referred to as Va14 invariant
(Va14i) NKT cells (Kronenberg, 2005). Glycolipid a-glac-
tosylceramide (aGalCer) presented by CD1d binds with
high avidity on Va14i NKT cells (Kronenberg, 2005). To
study the function of TGF-b signaling in Va14i NKT cell
development, we used CD1d-aGalCer tetramer to iden-
tify these cells. 20%–50% thymic Tetramer+TCR-bhi
Va14i NKT cells were present in 4cre-RII/RII mice com-
pared to their littermate controls (Figure 3C, top). The
spleens of 4cre-RII/RII mice were almost completely de-
void of Va14i NKT cells (Figure 3C, bottom). NKT cells
were also not detectable in the peripheral blood and
the livers of these mice (data not shown). These results
suggest that TGF-b signaling is required for the develop-
ment and homeostasis of Va14i NKT cells.
TGF-b Autonomously Maintained Peripheral
Treg Cells and Inhibited T Cell Activation
and Differentiation
Mice devoid of the Treg cell lineage, i.e., Foxp32/2 mice
(Fontenot et al., 2003), develop a similar autoimmune
phenotype as 4cre-RII/RII mice; we therefore wanted
to know whether the T cell activation phenotype in
4cre-RII/RII mice was a consequence of loss of periph-
eral Treg cells and/or was independent of Treg cells.
To this end, we purified wild-type CD4+CD25+ T cells
that were enriched for the Treg cell population from
the lymph nodes and spleens of C57BL/6 mice that ex-
pressed the congenic marker CD45.1 and transferred
them to 2-day-old 4cre-RII/RII or littermate control
mice that expressed CD45.2. Consistent with a more
dramatic reduction of Treg cells in the spleens than
the lymph nodes of 4cre-RII/RII mice (Figure 3A), trans-
ferred wild-type Treg cells selectively repopulated the
spleens of 4cre-RII/RII mice compared to the control
group (Figure 4A). However, even in the presence of
substantial numbers of splenic wild-type CD4+Foxp3+
Treg cells (Figure 4B, left), 4cre-RII/RII CD4+ T cells ex-
hibited an activated phenotype (Figure 4B, right). In ad-
dition, transfer of wild-type Treg cells did not alleviate
the lethal inflammation in 4cre-RII/RII mice (data not
shown). These observations suggest that depletion of
peripheral Treg cells in 4cre-RII/RII mice is not the sole
cause of the T cell activation and the autoimmune
phenotype.
In addition to Treg cells, TGF-b also controls other
subsets of regulatory T cell lineages, including NKT cells
(Figure 3C). To study whether TGF-b regulation of T cell
activation and differentiation is dependent on other non-
Treg regulatory T cell subsets, we generated mixed
bone marrow chimeric mice. Bone marrow cells from
CD45.2+ 4cre-RII/RII (KO) mice and CD45.1+ wild-type(B) Expression of Foxp3, CD45.2 (left), and CD44, CD62L (right) in splenic CD4+ T cells of 4cre-RII/+ and 4cre-RII/RII mice. CD45.2+ or CD45.22 T
cells represent host or donor T cells, respectively.
(C–F) Bone marrow chimeras were generated and analyzed.
(C) Development of immunopathology in mice reconstituted with wild-type (wt), 4cre-RII/RII (KO), or 1:1 mixed wt and KO bone marrow cells.
Hematoxylin and eosin staining of stomach and pancreas sections is shown (2003). These are representative results of three independent ex-
periments.
(D) Expression of Foxp3 and CD45.2 in splenic CD4+ T cells of wt, KO, or mixed bone marrow chimeras. A representative plot of six mice from
each group is shown.
(E) Expression of CD44 and CD62L in CD4+ T cells isolated from the lymph nodes of wt, KO chimeras, or of the wt or KO populations of the mixed
bone marrow chimera. These are representative results of three independent experiments.
(F) Expression of IFN-g in CD4+ T cells isolated from the lymph nodes of wt, KO chimeras, or of the wt or KO populations of the mixed bone mar-
row chimera. These are representative results of three independent experiments.
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nation into sublethally irradiated Rag12/2 recipients. All
chimeric mice reconstituted with KO bone marrow cells
developed severe wasting disease with infiltration of
leukocytes into multiple organs including stomach and
pancreas (Figure 4C) and succumbed to death within 5
weeks. In contrast, none of the recipients of wt bone
marrow cells developed disease (Figure 4C). Notably,
four out of seven mice of the mixed chimeras also devel-
oped severe inflammation in the same time frame
(Figure 4C). As expected, CD4+Foxp3+ Treg cells were
greatly reduced in KO chimeras compared to those in
wt chimeras (Figure 4D). Interestingly, the KO population
from the mixed chimera also had lower Treg cell num-
bers than the wt population of the same mouse (Fig-
ure 4D), demonstrating a cell-intrinsic role for TGF-b sig-
naling in the maintenance of Treg cells. In comparison to
the wt population, a marked increase in the number of
activated CD44hiCD62Llo CD4+ T cells and CD8+ T cells
(data not shown) were present in the KO population of
the mixed chimera, which was accompanied by the pro-
duction of higher amounts of IFN-g (Figures 4E and 4F).
Together, these observations reveal a cell-autonomous
function for TGF-b signaling in the maintenance of
Treg cells and in inhibiting CD4+ T cell activation and
Th1 cell differentiation, which is essential for the preven-
tion of autoimmune diseases.
An Essential Role for T-bet in Th1 Cell Differentiation
and Survival of CD4+ T Cells in 4cre-RII/RII Mice
Effector T cell differentiation is orchestrated by key tran-
scription factors, including T-bet for Th1 cells (Szabo
et al., 2000). Consistent with a dominant Th1 cell pheno-
type (Figure 2F), peripheral but not thymic 4cre-RII/RII
CD4+ T cells expressed high amounts of T-bet (Fig-
ure 5A). To determine the role of T-bet in these T cells,
we generated 4cre-RII/RII mice deficient in T-bet (en-
coded by Tbx21). Deficiency of T-bet did not rescue
the inflammatory phenotype or the Treg cell deficiency
of 4cre-RII/RII mice (Figures S2 and S3A). In fact, 4cre-
RII/RII Tbx212/2 mice developed an anemic phenotype
resulting in earlier lethality than 4cre-RII/RII mice (data
not shown). In addition, CD4+ T cell activation was not
altered in the absence of T-bet (Figure 5B), demonstrat-
ing that TGF-b inhibits T cell activation independent of
regulating the expression of T-bet. Compared to 4cre-
RII/RII CD4+ T cells, 4cre-RII/RII Tbx212/2 CD4+ T cells
had greatly reduced IFN-g-producing Th1 cells and in-
creased IL-4-producing Th2 cells (Figure 5C). This is
consistent with a role of T-bet in promoting Th1 while
suppressing Th2 cell differentiation (Finotto et al.,
2002). It is therefore possible that Th2 effector T cells
and/or activated CD8+ T cells may be responsible for
the immunopathology in 4cre-RII/RII Tbx212/2 mice.
Intriguingly, deficiency of T-bet in 4cre-RII/RII mice
also led to a reduced ratio of splenic CD4+ T cells to
CD8+ T cells, which was not observed in Tbx212/2
mice (Figure 5D). A similar reversed CD4+/CD8+ T cell ra-
tio was also observed in the lymph nodes, peripheral
blood, and livers of these mice (Figure S3B), suggesting
that diminished splenic CD4+ T cells was not due to al-
tered traffic of T cells to other tissues. In contrast to
the expanded CD4+ T cell compartment in 4cre-RII/RII
mice, but consistent with the change in the CD4+/CD8+ratio, 4cre-RII/RII Tbx212/2 spleens had reduced num-
ber of CD4+ T cells (Figure 5E). This was a specific defect
for CD4+ T cells; CD8+ T cell number increased in both
4cre-RII/RII and 4cre-RII/RII Tbx212/2 mice (Figure 5E).
These observations suggest that T-bet is required not
only for the Th1 cell differentiation but also for the sur-
vival of CD4+ T cells in 4cre-RII/RII mice.
Il2rb, a Direct Target Gene of T-bet, Enabled IL-15
Signaling and Th1 Cell Survival
In CD8+ T cells, T-bet and its paralogue eomesodermin
regulate the expression of CD122 (Intlekofer et al.,
2005), the receptor b chain for interleukin 15 (IL-15)
and IL-2. T-bet also regulates the expression of CD122
in Th1 cells differentiated in vitro (L. Glimcher and G.M.
Lord, personal communication). The IL-15-CD122 path-
way is important in the homeostasis of effector and
memory CD8+ T cells (Judge et al., 2002; Ku et al.,
2000), but its function in CD4+ T cells remains largely un-
defined in vivo. To investigate whether the defective sur-
vival of CD4+ T cells in 4cre-RII/RII Tbx212/2 mice was
associated with compromised CD122 expression, we
compared surface CD122 expression in these T cells
by FACS analysis (Figure 6A). Although there were only
a small percentage of CD4+ T cells expressing CD122
in wild-type or Tbx212/2 mice, almost all splenic CD4+
T cells expressed high amounts of CD122 in 4cre-RII/
RII mice (Figure 6A, left). CD122 expression was mark-
edly reduced in CD4+ T cells from 4cre-RII/RII Tbx212/2
mice (Figure 6A, left). In contrast, the expression of
CD122 on CD8+ T cells in 4cre-RII/RII Tbx212/2 mice
was not changed and thus was not solely dependent
on T-bet (Figure 6A, right). These observations are con-
sistent with the specific reduction of CD4+ but not CD8+
T cell number in 4cre-RII/RII Tbx212/2 mice (Figures 5D
and 5E).
The increased CD122 expression in 4cre-RII/RII CD4+
T cells rendered them responsive to IL-15 and IL-2, be-
cause both IL-2 and IL-15 stimulated the proliferation
of 4cre-RII/RII CD4+ T cells in vitro as revealed by
CFSE dilution (Figure 6B, left), whereas naive wild-type
CD4+ T cells were not responsive to these cytokines
(data not shown). More viable cells were recovered
from the wells that were treated with IL-15 than IL-2 or
antigen-presenting cell (APC) alone (Figure 6B, middle),
suggesting that IL-15 treatment also promoted the sur-
vival of 4cre-RII/RII CD4+ T cells. Consistent with re-
duced CD122 expression on 4cre-RII/RII Tbx212/2
CD4+ T cells, IL-15 had minimal effect on these cells
(Figure 6B, right). To investigate the function of IL-15
on survival of these cells in vivo, we labeled 4cre-RII/
RII CD4+ T cells with CFSE and transferred them into
sublethally irradiated wild-type or Il152/2 mice. 4cre-
RII/RII CD4+ T cells proliferated extensively in both
wild-type and Il152/2 hosts as revealed by CFSE dilution
(Figure 6C, left). However, reduced numbers of 4cre-RII/
RII CD4+ T cells were recovered from Il152/2 mice com-
pared to wild-type mice (Figure 6C, right). These obser-
vations suggest an important role of the IL-15-CD122
pathway in regulating the survival of 4cre-RII/RII CD4+
T cells in vivo.
To further explore the molecular mechanisms by
which TGF-b can modulate CD122 expression via T-
bet in 4cre-RII/RII CD4+ T cells, we first studied T-bet
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463Figure 5. Requirement of T-bet for Th1 Cell Differentiation and CD4+ T Cell Survival in 4cre-RII/RII Mice
(A) Expression of T-bet in CD4+ T cells from RII/RII (wt) and 4cre-RII/RII (KO) mice at 14 days old. The amounts of T-bet and HDAC-1 were de-
termined by immunoblotting from thymic (Thy) and peripheral (SP + LN) CD4+ T cell extracts.
(B) Expression of CD44 and CD62L in splenic CD4+ T cells from RII/RII (wt), Tbx212/2, 4cre-RII/RII, and 4cre-RII/RII Tbx212/2mice at 16 days old.
These are representative results of five independent experiments.
(C) Expression of IFN-g and IL-4 in CD4+ T cells isolated from the lymph nodes of RII/RII (wt), Tbx212/2, 4cre-RII/RII, and 4cre-RII/RII Tbx212/2
mice. These are representative results of two independent experiments.
(D) The percentage of CD4+ and CD8+ splenic T cells in RII/RII (wt), Tbx212/2, 4cre-RII/RII, and 4cre-RII/RII Tbx212/2 mice. The ratios of CD4+ T
cells to CD8+ T cells are shown. These are representative results of five independent experiments.
(E) The number of CD4+ and CD8+ splenic T cells in RII/RII (wt), Tbx212/2, 4cre-RII/RII, and 4cre-RII/RII Tbx212/2 mice at 16 days old (n = 4).regulation of CD122 expression in in vitro differentiated
wild-type CD4+ T cells. High expression of CD122 was
found in Th1 but not in Th2 cells differentiated from
wild-type naive CD4+ T cells isolated from C57BL/6
mice (Figure 6D, left). Inclusion of TGF-b1 in Th1 cell cul-
ture inhibited CD122 expression almost entirely(Figure 6D, right). This is consistent with high CD122 ex-
pression in 4cre-RII/RII CD4+ T cells (Figure 6A), which
we showed to have differentiated into Th1 cells
(Figure 2F), and with our previous finding that TGF-b1 in-
hibits T-bet expression and Th1 cell differentiation (Gor-
elik et al., 2002). To study whether increased CD122
Immunity
464Figure 6. T-bet Regulation of CD122 Expression and IL-15 Responsiveness in Th1 Cells
(A) Expression of CD122 in splenic CD4+ (left) and CD8+ (right) T cells of RII/RII (wt), Tbx212/2 (T-bet KO), 4cre-RII/RII (RII KO), and 4cre-RII/RII
Tbx212/2 (RII T-bet KO) mice. This is a representative plot of four mice from each group.
(B) 4cre-RII/RII CD4+ T cells (RII KO) were CFSE labeled and cultured with antigen-presenting cells (APCs) in the absence or presence of IL-2 or
IL-15 for 3 days. The amounts of CFSE (left) and the relative recovery of viable cells (middle) in these cultures are shown. 4cre-RII/RII Tbx212/2
CD4+ T cells (RII T-bet KO) were cultured with APCs in the absence or presence of IL-2 or IL-15 for 3 days. The relative recovery of viable cells
(right) is shown. These are representative results of two independent experiments. The error bars have been calculated with Excel STDEV, which
gives the standard deviation.
(C) 4cre-RII/RII CD4+ T cells were CFSE labeled and transferred into sublethally irradiated wild-type (wt) or Il152/2mice. The representative CFSE
profile of the transferred CD4+ T cells in the blood at day 3 is shown (left). The percentage of the transferred CD4+ T cells in the wt or Il152/2
recipients is depicted (n = 5, right).
(D) Naive CD4+ T cells isolated from C57BL/6 mice were cultured under Th1 or Th2 conditions for 4 days (left) or Th1 condition in the absence or
presence of TGF-b (right), and CD122 expression was compared between different conditions. These are representative results of two indepen-
dent experiments.
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465expression in Th1 cells conferred their growth or survival
advantage in response to IL-15 or IL-2, day 4 Th1 or Th2
cells were purified and recultured in the absence or
presence of these cytokines. Increased viable Th1 cells
but not Th2 cells were recovered when IL-15 was added
to the cultures, and to a less extent when IL-2 was added
(Figure S4A). These observations reveal that the IL-15-
CD122 pathway selectively regulates the survival of
Th1 cells.
To determine whether expression of T-bet was suffi-
cient to induce CD122 expression under nonpermissive
conditions, we transduced Th2 cells with a control or
T-bet-expressing retrovirus and cultured these cells
for another 3 days. Cells transduced with the T-bet ret-
rovirus expressed higher amounts of CD122 than cells
transduced with the control virus (Figure 6E), suggesting
that T-bet may directly control CD122 expression. High
amount of CD122 mRNA was found in 4cre-RII/RII
CD4+ T cells, which was substantially decreased in
4cre-RII/RII Tbx212/2 CD4+ T cells (Figure 6F). Thus, in-
creased CD122 surface expression in 4cre-RII/RII CD4+
T cells was at least partly mediated by T-bet-dependent
CD122 transcription. Several putative T-box transcrip-
tion factor binding sites are present in the promoter re-
gion of the gene encoding CD122 (Il2rb) (Intlekofer
et al., 2005). Eomesodermin is associated with the
Il2rb promoter in CD8+ T cells (Intlekofer et al., 2005).
T-bet binds to Il2rb promoter in Th1 cells differentiated
in vitro (L. Glimcher and G.M. Lord, personal communi-
cation). To investigate whether T-bet directly binds to
the Il2rb promoter in 4cre-RII/RII CD4+ T cells, we per-
formed chromatin immunoprecipitation with a T-bet-
specific antibody. Genomic fragments containing Il2rb
promoter were highly enriched in 4cre-RII/RII CD4+ T
cells but not in the control T cells with the T-bet antibody
(Figure S4B). In contrast, the promoter of the Il4 gene,
which is not a T-bet target, was only marginally enriched
(Figure S4B). The augmented association of T-bet with
Il2rb promoter in 4cre-RII/RII CD4 T cells supports
Il2rb as a T-bet target gene in these cells.
Treg Cell-Independent TGF-b Regulation
of OT-II T Cell Activation and Survival
Because TGF-b signaling affected thymic T cell develop-
ment (Figures 2 and 3), it was possible that the periph-
eral T cell repertoire was altered in 4cre-RII/RII mice. In
addition, in a Treg cell-centric view of peripheral T cell
tolerance, the autonomous TGF-b regulation of T cell ac-
tivation and differentiation (Figure 4) might simply reflect
the requirement of TGF-b signaling for the suppressive
function of Treg cells, as suggested by recent studies
(Green et al., 2003; Chen et al., 2005; Fahlen et al.,
2005; von Boehmer, 2005). In addition, previously re-
ported studies of TGF-b on T cells in vitro were compli-
cated by the fact that TGF-b induces Foxp3 expression
and the differentiation of Treg cells in in vitro cultures
(Chen et al., 2003; Fantini et al., 2004; Wan and Flavell,
2005). Therefore, it was not known whether TGF-b couldregulate T cells independent of Treg cells. To address
these questions, we crossed 4cre-RII/RII mice with
OT-II (CD4+ TCR specific for OVA peptide) transgenic
mice onto Rag12/2 background, in order to exclude
the T cell repertoire as a variable. 4cre-RII/RII OT-II T
cells had no detectable surface expression of TGF-
bRII (Figure S5A), revealing efficient deletion of TGF-
bRII in these cells. Abrogation of TGF-bRII expression
did not markedly affect thymic OT-II T cell development
as determined by the expression of CD4, CD8, and TCR-
b (Figure S5B and data not shown). Both RII/RII OT-II
and 4cre-RII/RII OT-II T cells failed to differentiate into
Foxp3-expressing Treg cells (Figure S5C), which ren-
dered these mice an ideal model for the study of Treg
cell-independent TGF-b regulation of T cell function.
In contrast to RII/RII OT-II T cells, most of which had
a naive CD44loCD62Lhi phenotype, a substantial propor-
tion of splenic 4cre-RII/RII OT-II T cells exhibited an acti-
vated CD44hiCD62Llo phenotype (Figure 7A). To deter-
mine whether 4cre-RII/RII OT-II T cells differentiated
into effector Th1 or Th2 cells, we stimulated splenic
OT-II T cells with PMA and ionomycin for 4 hr and per-
formed intracellular cytokine staining with IFN-g and IL-
4 antibodies. The majority of 4cre-RII/RII OT-II T cells
did not differentiate into either Th1 or Th2 cells in com-
parison to the dominant Th1 cell phenotype of polyclonal
CD4+ T cells from 4cre-RII/RII mice (Figure 7B). Lack of
effector T cell differentiation of 4cre-RII/RII OT-II T cells
was likely due to the absence of cognate antigens in
vivo, because stimulation of these T cells with OVA pep-
tide led to their differentiation into Th1 cells in vitro
(Figure S5D). The majority of 4cre-RII/RII OT-II T cells
also did not upregulate CD122 compared to RII/RII OT-
II T cells (Figure 7C), which was consistent with the find-
ing that CD122 was selectively expressed in Th1 cells.
Therefore, abrogation of TGF-b signaling in OT-II T cells
led to their partial activation but not differentiation into
Th1 or Th2 cells.
Because we observed reduced number of CD4+ T
cells in 4cre-RII/RII Tbx212/2 mice associated with
lack of Th1 differentiation and CD122 expression (Fig-
ures 5 and 6A), we investigated whether loss of TGF-
b signaling in OT-II cells would affect their survival. Com-
pared to RII/RII OT-II mice, the number of OT-II T cells
was greatly reduced in the spleens and lymph nodes
of 4cre-RII/RII OT-II mice (Figure 7D) and in the blood
by 80%–90% (Figure 7D). We observed a 3- to 4-fold in-
crease of annexinV-positive T cells in 4cre-RII/RII OT-II T
cells compared to RII/RII OT-II T cells (Figure 7E), sug-
gesting that the diminished number of T cells was due
to increased apoptosis. These observations revealed
an essential function for TGF-b signaling in promoting
survival of peripheral OT-II T cells.
Discussion
Because of the diverse effects of TGF-b on multiple lin-
eages of hemopoietic cells (Li et al., 2006), it has been(E) Naive CD4+ T cells were cultured under nonpolarizing conditions for 24 hr, transduced with T-bet or control retrovirus (RV), and recultured
under Th2 conditions for 3 days. The expression of CD122 in GFP+ (cells infected with retrovirus) and GFP2 populations is plotted.
(F) The relative expression of CD122 mRNA in CD4+ T cells of RII/RII (wt), Tbx212/2, 4cre-RII/RII, or 4cre-RII/RII Tbx212/2 mice was determined
by quantitative RT-PCR. These are representative results of two independent experiments. The error bars have been calculated with Excel
STDEV, which gives the standard deviation.
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(A) Expression of CD44 and CD62L in splenic RII/RII OT-II and 4cre-RII/RII OT-II T cells. These are representative results of five independent
experiments.
(B) Splenic RII/RII OT-II, 4cre-RII/RII OT-II, 4cre-RII/+ CD4+, and 4cre-RII/RII CD4+ T cells were stimulated with PMA and ionomycin for 4 hr and
analyzed for the expression of IFN-g and IL-4 by intracellular cytokine staining.
(C) Expression of CD122 in splenic RII/RII OT-II (RII WT OT-II), 4cre-RII/RII OT-II (RII KO OT-II), 4cre-RII/+ CD4+ (RII Het), and 4cre-RII/RII CD4+
(RII KO) T cells.
(D) Number of OT-II T cells in the spleens (SP) and the lymph nodes (LN) of 4cre-RII/RII OT-II (KO), or littermate RII/RII OT-II and 4cre-RII/+ OT-II
(control) mice (n = 4). The percentage of blood OT-II T cells among white blood cells (WBC) is also plotted.
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467very difficult to assess the role of TGF-b signaling on T
cells with Tgfb12/2 mice. TGF-b has pleiotropic effects
on T cells in vitro. In addition to the well-documented
suppressive activity, studies have revealed positive
functions for TGF-b on T cell differentiation (Halverson
et al., 1997; Lingnau et al., 1998; Veldhoen et al., 2006),
expansion, and/or survival (Cerwenka et al., 1994,
1996). Although the dominant-negative models (dis-
cussed in the Introduction) have helped to identify
TGF-b as one of the most important molecules involved
in T cell tolerance in vivo, the underlying mechanisms
are not well understood. We have used the cre-loxp sys-
tem to delete TGF-bRII in T cells and have explored its
role in thymic T cell development and peripheral T cell
activity. We found that TGF-b signaling promoted
CD8+ T cell maturation and NKT cell development, while
inhibiting Treg cell proliferation in the thymus. The TGF-
b signaling in T cells also maintained peripheral Treg
cells, as well as inhibiting T cell proliferation, activation,
and differentiation in a cell-autonomous manner, lack of
which led to severe autoimmunity and early lethality in
mice. Transcription factor T-bet regulated both Th1 dif-
ferentiation and the survival of CD4+ T cells in the ab-
sence of TGF-b signaling, which was associated with
the induction of CD122 expression. Inhibition of TGF-
b signaling in OT-II T cells resulted in their partial activa-
tion and marked apoptosis without differentiation into
Th1 or Th2 cells. Our findings reveal previously unde-
scribed potent and pleiotropic roles of TGF-b in T cells
in vivo, which have important implications for our under-
standing of TGF-b regulation of T cell development, tol-
erance, and homeostasis.
Inhibition of TGF-b signaling caused reduced number
of thymic mature CD8+ T cells and impaired NKT cell de-
velopment. A recent study with the transfer of TGF-bRII-
deficient bone marrow cells concluded no thymocyte
developmental defects in the absence of TGF-b signal-
ing, although it reveals increased proliferation of CD8+
thymocytes (Leveen et al., 2005). Importantly, in that re-
port CD8+ T cells were not separated into mature and
immature single-positive T cells (ISPs). Since ISPs cycle
more actively than mature T cells (Paterson and Wil-
liams, 1987), a defect in CD8+ T cell maturation would
lead to increased ISPs and the hyperproliferation phe-
notype of CD8+ thymocytes. The mechanisms by which
TGF-b regulates NKT cell development and CD8+ T cell
maturation remain to be defined. Signaling pathways
originated from TCR and cytokines such as IL-7 critically
regulate T cell-positive selection and lineage commit-
ment (Aliahmad and Kaye, 2006). The potential crosstalk
of TGF-b and these pathways in T cell development is
currently under investigation.
Recent studies have highlighted a pivotal role for Treg
cell-mediated immune suppression in peripheral T cell
tolerance (Sakaguchi, 2004). However, signaling path-
ways that regulate Treg cell development and homeo-
stasis remain largely undefined (Fontenot and Ruden-
sky, 2005). Here we show that TGF-b signaling in T
cells inhibited proliferation and expansion of Treg cells
in the thymus, while it autonomously maintained Treg
cells in peripheral tissues. Expansion of thymic Tregcells was not reported in Tgfb12/2 mice (Marie et al.,
2005). It is possible that TGF-b2 and TGF-b3 may com-
pensate for TGF-b1 in inhibiting the expansion of thymic
Treg cells, as indicated by the fact that the activity of all
three TGF-bs is blocked in our model of 4cre-RII/RII con-
ditional knockout mice. Consistent with our findings, it
was reported that Treg cells are reduced in the periphery
of Tgfb12/2 mice (Marie et al., 2005). We further showed
that reduced peripheral Treg cells in 4cre-RII/RII mice
was not due to impaired proliferation of these cells; in
fact, they underwent hyperproliferation. These observa-
tions suggested that the TGF-b pathway might be es-
sential for the survival of peripheral Treg cells, which is
supported by recent in vitro studies (Fu et al., 2004;
Zheng et al., 2002). Alternatively, TGF-bmay be required
for the expression of Foxp3 and the prevention of Treg
cells to differentiate into effector T cells, or the genera-
tion of Treg cells from naive T cells in the periphery
(Kretschmer et al., 2005). Under either circumstance,
the requirement of TGF-b signaling for the maintenance
of Treg cells defines an important mechanism for TGF-b-
induced T cell tolerance.
In addition to the maintenance of Treg cells, TGF-b au-
tonomously inhibited T cell activation and differentia-
tion. These findings revealed a cell-intrinsic requirement
for TGF-b signaling in both Treg cells and naive T cells
for maintaining T cell tolerance. In the absence of TGF-
b signaling, CD4+ T cells upregulated T-bet, differenti-
ated into Th1 cells, and hyperproliferated. Here we dem-
onstrate that T-bet regulated CD122 expression in Th1
cells and enabled these cells to respond to IL-15 and
IL-2. These findings define a new role for IL-15 signaling
in Th1 cells that is regulated by TGF-b. It is noteworthy
that there is T-bet-independent CD122 expression in
4cre-RII/RII CD8+ T cells and to a less extent in CD4+ T
cells. A recent study showed that both T-bet and its pa-
ralogue eomesodermin regulate CD122 expression in
CD8+ T cells (Intlekofer et al., 2005). Therefore, it is pos-
sible that in addition to T-bet, eomesodermin is capable
of inducing CD122 expression in 4cre-RII/RII T cells,
a hypothesis that is currently under investigation.
The nature of the antigens that drive the expansion
and differentiation of effector T cells in 4cre-RII/RII
mice remains to be fully characterized. Intriguingly,
4cre-RII/RII OT-II T cells on the Rag12/2 background
were partially activated but not differentiated into Th1
or Th2 cells, which demonstrates that effector T cell dif-
ferentiation is not a default pathway in the absence of
TGF-b signaling. Stimulation of 4cre-RII/RII OT-II T cells
with OVA peptides led to their differentiation to Th1 cells
in vitro, suggesting that defective differentiation of 4cre-
RII/RII OT-II T cells in vivo may be due to the absence of
the cognate antigen stimulation.
Strikingly, TGF-bRII-deficient OT-II T cells underwent
extensive apoptosis and were markedly depleted in pe-
ripheral tissues. Similar depletion of CD4+ T cells was
also found in 4cre-RII/RII Tbx212/2 mice in which CD4+
T cells failed to differentiate into Th1 cells. In both cases,
CD122 expression was diminished compared to that of
4cre-RII/RII CD4+ T cells. Based on these observations,
we hypothesize that lack of TGF-b signaling results in(E) Splenic T cells from RII/RII OT-II or 4cre-RII/RII OT-II mice were gated by CD4 and TCR-b staining and analyzed for the presence of apoptotic
cells by annexinV staining. These are representative results of two independent experiments.
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468apoptosis of CD4+ T cells unless they differentiate into
Th1 cells, which express T-bet and can be rescued
from apoptosis by IL-15 signaling via CD122 upregula-
tion. The effects of TGF-b signaling on CD4+ T cell sur-
vival and differentiation may ensure a diverse and self-
tolerant T cell repertoire in vivo, the lack of which results
in the accumulation of effector CD4+ Th1 cells in 4cre-RII/
RII mice. We have shown that TGF-b inhibits CD8+ T cell
activation and differentiation. It remains to be deter-
mined whether TGF-b also regulates CD8+ T cell survival.
Interestingly, in 4cre-RII/RII mice, CD8+ T cells were
more actively cycling than CD4+ T cells, yet CD8+ T cells
expanded similarly to CD4+ T cells, suggesting that CD8+
T cells underwent higher rates of apoptosis than CD4+ T
cells in the absence of TGF-b signaling. Collectively,
these observations suggest that loss of peripheral T
cell tolerance in 4cre-RII/RII mice is likely a combined ef-
fect of TGF-b regulation of T cell survival and effector T
cell differentiation.
The mechanisms involved in TGF-b regulation of T cell
survival remain to be determined. Previous studies with
Tgfb12/2 mice showed increased thymic and peripheral
T cell apoptosis associated with T cell activation (Chen
et al., 2001). It is possible that increased T cell apoptosis
in the absence of TGF-b signaling is a consequence of
activation without effector T cell differentiation. How-
ever, we did not observe upregulation of death receptors
Fas or TRAIL in 4cre-RII/RII OT-II T cells (unpublished
observations), which are involved in activation-induced
cell death. It is therefore possible that TGF-b may pro-
mote naive T cell survival independent of T cell activa-
tion. However, we conclude that TGF-b regulation of T
cell activation and survival in 4cre-RII/RII mice is most
likely Treg cell independent, since Treg cells were not
present in OT-II Rag12/2 mice, and in a similar vein,
deficiency of Foxp3 did not perturb OT-II T cell homeo-
stasis (Fontenot et al., 2005).
In conclusion, in this report we have defined a multi-
faceted role for TGF-b signaling in T cell development,
tolerance, and homeostasis and have revealed novel
mechanisms by which TGF-b controls CD4+ T cell differ-
entiation and survival. These findings will advance our
knowledge on the function of TGF-b in the immune sys-
tem and can be exploited for the immunotherapy of au-
toimmune diseases and cancer.
Experimental Procedures
Mice
Floxed TGF-bRII mice, CD4-Cre transgenic mice, Tbx212/2 mice,
and OT-II transgenic mice were previously reported (Barnden
et al., 1998; Chytil et al., 2002; Lee et al., 2001; Szabo et al., 2002).
C57BL/6 CD45.1 congenic mice and Il152/2 mice were obtained
from Taconic Farms. Mice used in the transfer experiments have
been backcrossed to C57BL/6 background for 5 to 6 generations.
All mice were maintained under specific pathogen-free conditions.
All animal experimentation was conducted in accordance with insti-
tutional guidelines.
Histopathology
Tissues from sacrificed animals were fixed in Streck Tissue Fixative
(Streck Laboratories) and embedded in paraffin. 5 mm sections were
stained with hematoxylin and eosin.
ELISA
The amounts of dsDNA antibody in mouse sera were determined
with an ELISA kit from Alpha Diagnostic International. Sera fromeight 4cre-RII/RII and eight littermate control mice aged from day
21 to 26 were assayed individually with 1:100 dilution in 1% BSA
PBS.
Immunoblotting
To analyze Smad2 and Smad3 and T-bet expression, nuclear ex-
tracts were prepared as previously described (Li et al., 2001). 5 mg
protein extract was separated on 4%–12% Bis-Tris NuPAGE Gels
(Invitrogen) and transferred to PVDF membrane (Millipore). Mem-
branes were probed with Smad2 and Smad3 antibody (clone 18,
BD Transduction Laboratories) and T-bet antibody (clone 4B10,
Santa Cruz Biotechnology). Subsequently, the membranes were
striped with Restore Western Blot Stripping Buffer (Pierce) and re-
probed with HDAC-1 antibody (Sigma).
Quantitative RT-PCR
CD4+ T cells were purified with anti-CD4 microbeads (Miltenyi Bio-
tec). RNA was isolated with RNeasy Mini Kit (Qiagen) and reverse
transcribed into cDNA with proSTAR First-Strand RT-PCR Kit (Stra-
tagene) according to the manufacturer’s instructions. Presynthe-
sized Taqman Gene Expression Assay (Applied Biosystems) was
used to amplify mouse CD122 mRNA (Il2rb; Mm00434264_m1). Hy-
poxanthine phosphoribosyltransferase (Hprt) was used as an inter-
nal reference and measured with the primers 50-CTGGTGAAAAG
GACCTCTCG-30 and 50-TGAAGTACTCATTATAGTCAAGGGCA-30
at a final concentration of 200 nM and with the TaqMan probe 50-
FAM-TGTTGGATACAGGCCAGACTTTGTTGGAT-BHQ-1-30 at a final
concentration of 200 nM. Relative expression of Il2rb normalized to
Hprt was presented.
Chromatin Immunoprecipitation
CD4+ T cells were fixed for 10 min at room temperature with 10%
formaldehyde in 0.1 M NaCl, 1 mM EDTA, 0.5 mM EGTA, and 50
mM HEPES. After incubation, glycine was added to a final concen-
tration of 0.125 M to ‘‘quench’’ the formaldehyde for 5 min. Cells
were pelleted, washed once with ice-cold PBS, and lysed on ice
for 10 min with lysis buffer A (10 mM Tris [pH 8], 10 mM EDTA,
0.5 mM EGTA, 0.25% Triton, 0.5% NP40, and the protease inhibitors
[PIs] from Roche). Lysates were pelleted and washed once in lysis
buffer B (10 mM Tris [pH 8], 1 mM EDTA, 0.5 mM EGTA, 0.2 M
NaCl, and PIs) before being resuspended in the sonication buffer
(10 mM Tris [pH 8], 1 mM EDTA, 0.5 mM EGTA, and PIs). Lysates
were sonicated to reduce DNA length to between 500 and 1000
base pairs. The soluble fraction was reconstituted with 0.5% sarco-
syl and 5% glycerol, and aliquoted. 20 mg of the chromatin was pre-
cleared with protein A and protein G agarose beads in RIPA.IP buffer
(1% Triton, 0.1% DOC, 140 mM NaCl, and PIs) for 1 hr, and was then
incubated with 5 mg of T-bet antibody (clone 4B10, Santa Cruz Bio-
technology). Immune complexes were precipitated with protein A
and protein G agarose beads preblocked in RIPA.IP buffer with 20
mg/ml salmon sperm DNA and 20 mg/ml BSA. Immunoprecipitates
were washed seven times in the RIPA wash buffer (1% Triton,
0.1% DOC, 500 mM NaCl, 0.1% SDS, and PIs), and eluted in 100 ml
of TE with 0.5% SDS and 200 mg/ml proteinase K. Precipitated
DNA was further purified with phenol/chloroform extranction and
ethanol precipitation and was analyzed by PCR. The primers used
in the analysis of binding included: Il2rb, 50-GTGCTCATGCGTGAG
CAGAAG-30 and 50-GCCCACTTCCTGTATAGAGGATG-30; Il4, 50-
AGAAGGTCTGCCTCCATCATCC-30 and 50-TTATCAGCGTAGGGTT
GCCACTGG-30.
T Cell Culture and Retroviral Transduction
Splenic and lymph node CD4+ T cells were enriched by positive se-
lection with anti-CD4 microbeads (Miltenyi Biotec). Naive T cells
were further purified from C57BL/6 mice with a cell sorter (Becton
Dickinson) by gating on the CD4+CD25-CD62LhiCD44lo population.
For Th1 culture, 3 3 105 CD4+ T cells were stimulated with 3 3 106
irradiated antigen-presenting cells (APCs) in the presence of 100
u/ml IL-2, 35 ng/ml IL-12, 5 mg/ml CD3, 2 mg/ml CD28, and 10 mg/
ml IL4 antibodies (11B11 clone) for 4 days. Th1 cells were also differ-
entiated in the presence of TGF-b1 for 4 days (2 ng/ml). For Th2 cul-
ture, CD4+ T cells were stimulated with APCs in the presence of 100
u/ml IL-2, 1000 u/ml IL-4, 5 mg/ml CD3, 2 mg/ml CD28, and 10 mg/ml
IFN-g antibodies (XMG clone) for 4 days. Th1 or Th2 cells were Ficoll
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469purified and cultured in the absence or presence of IL-15 (20 ng/ml)
or IL-2 (100 U/ml) for 3 days. For retroviral transduction experiments,
CD4+ T cells were stimulated with APCs in the presence of 100 u/ml
IL-2, 5 mg/ml CD3, and 2 mg/ml CD28 antibodies. At 24 hr after stim-
ulation, T cells were resuspended in T-bet or control retroviral super-
natant and subjected to spin infection. Subsequently, cells were cul-
tured in fresh medium under Th2 conditions for 3 days. For the
analysis of 4cre-RII/RII or 4cre-RII/RII Tbx212/2 T cells, mi-
crobead-purified CD4+ T cells were labeled with CFSE and cultured
with APCs in the absence or presence of IL-15 or IL-2 for 3 days. For
the differentiation of OT-II T cells in vitro, RII/RII OT-II or 4cre-RII/RII
OT-II T cells were purified by positive selection with anti-CD4 mi-
crobeads, and splenic dendritic cells were purified from C57BL/6
mice with anti-CD11c microbeads (Miltenyi Biotec). 1 3 105 OT-II T
cells were cocultured with 2 3 105 dendritic cells in the presence
of 0.05 mM OVA peptides (ISQAVHAAHAEINEAGR) for 3 days.
BrdU Labeling
Day 16 4cre-RII/RII or littermate control mice were given 50 mg/kg
BrdU by i.p. injection. 16 hr later, thymic, splenic, and lymph node
T cells were prepared and analyzed.
Flow Cytometry
Cells from spleens, lymph nodes, or thymus were depleted of eryth-
rocytes by hypotonic lysis. Cells were incubated with specific anti-
bodies for 30 min on ice in the presence of 2.4G2 mAb to block
FcgR binding. All samples were analyzed with FACSCalibur (Becton
Dickinson) and FloJo (Tree Star) software. All antibodies were ob-
tained from BD Biosciences PharMingen with the exception of bio-
tinylated mouse TGF-bRII antibody (R&D Systems), Foxp3 antibody
(e-Biosciences), and BrdU antibody (Becton Dickinson). PE-labeled
Cd1d-aGalCer was kindly provided by Dr. M. Kronenberg (La Jolla
Institute for Allergy and Immunology). For intracellular cytokine
staining, single-cell suspensions of spleens or lymph nodes were
stimulated with 50 ng/ml phorbol 12-myristate 13-acetate (PMA,
Sigma) and 1 mM ionomycin (Sigma) for 4 hr; GolgiStop (BD Biosci-
ences PharMingen) were added for the final 2 hr of culture. After
stimulation, cells were first stained with CD4, CD8, TCR-b, and
CD45.2 antibodies, then fixed and permeabilized with a Cytofix/Cy-
toperm kit (BD Biosciences PharMingen), and finally stained with
IFN-g and IL-4 antibodies. Mice were also injected i.p. with 0.25
mg Brefeldin A (Sigma). 6 hr later, peripheral T cells were harvested
and stained with IFN-g and IL-4 antibodies. Intracellular Foxp3 stain-
ing was carried out with a kit from e-Biosciences. After Foxp3 stain-
ing, some of the cells were also stained with BrdU antibody. To an-
alyze cell apoptosis, cells were stained with FITC-labeled annexin V
(BD Biosciences PharMingen) according to the manufacturer’s
instructions.
Adoptive Transfer of T Cells
Splenic and lymph node CD45.1+CD4+CD25+ T cells were purified
with microbeads. 3 3 105 T cells were injected i.p. to 2-day-old
CD45.2+ 4cre-RII/RII or littermate control mice. These mice were
monitored for the development of disease and analyzed at day 21
of age. Splenic and lymph node 4cre-RII/RII CD4+ T cells were puri-
fied with microbeads and labeled with CFSE. 23 106 T cells were in-
jected i.v. to C57BL/6 or Il152/2mice that were irradiated at 700 rad 1
day before the transfer. 3 days later, these mice were bled and ana-
lyzed for the proliferation and the recovery of the transferred T cells.
Generation of Bone Marrow Chimeras
Bone marrow cells isolated from 6-week-old CD45.1+ C57BL/6 (wt)
mice or 3-week-old CD45.2+ 4cre-RII/RII (KO) mice were depleted
of erythrocytes by hypotonic lysis and T cells and antigen-present-
ing cells by complement-mediated cell lysis. 2 3 106 wt, KO, or 1:1
mixed wt and KO bone-marrow cells were injected i.v. to 6- to 8-
week-old sublethally irradiated (600 rad) Rag12/2 mice. Reconsti-
tuted mice were maintained on autoclaved Sulfatrim-containing wa-
ter for 2 weeks and on regular water afterwards.
Statistical Analyses
Student’s t test was used to calculate statistical significance for
difference in a particular measurement between groups. p value of
%0.05 was considered statistically significant.Supplemental Data
Six Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/25/3/455/DC1/.
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